NHS Wegovy Eligibility: Who Qualifies in 2026 and How to Get It

The NHS will eventually cover GLP-1 medications at scale. The clinical evidence is overwhelming, the NICE approval is in place, and the long-term health economics are compelling. But "eventually" may mean two years, or longer. Here is what the criteria actually are, how the pathway works, and what your realistic options look like right now.

The Official NICE Criteria (TA875)

NICE Technology Appraisal 875, published in March 2023, approved semaglutide 2.4 mg (Wegovy) for use on the NHS for chronic weight management in adults. This is not a blanket approval. It comes with specific eligibility criteria that must be met.

The primary criteria are:

1. BMI of 35 kg/m² or more, with at least one weight-related comorbidity
2. OR BMI of 40 kg/m² or more (no comorbidity requirement)

Weight-related comorbidities that qualify include:

• Type 2 diabetes (pre-diabetes counts in some interpretations)
• Hypertension requiring medication
• Dyslipidaemia (raised cholesterol or triglycerides on or needing treatment)
• Obstructive sleep apnoea
• Cardiovascular disease (history of heart attack, stroke, or established coronary artery disease)
• Non-alcoholic fatty liver disease
• Polycystic ovary syndrome (PCOS) with documented metabolic complications

The secondary criteria:

• Treatment must be delivered as part of a specialist weight management service (not GP-only prescribing in most areas)
• Treatment should be combined with a reduced-calorie diet and increased physical activity
• NICE recommends treatment for a maximum of 2 years, with reassessment at that point

Who is excluded:

• Pregnancy or breastfeeding
• Type 1 diabetes
• A personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Eating disorders (active)
• Severe renal impairment (eGFR below 15)
• Concurrent use of other GLP-1 receptor agonists

What "Specialist Weight Management Service" Actually Means

This is the part of the pathway that catches most people out. Unlike many NICE-approved medications that can be prescribed by GPs, Wegovy under TA875 is intended to be delivered through specialist weight management services, also called Tier 3 services in the NHS commissioning structure.

Tier 3 weight management services include:

• Specialist dietitian support
• Psychological input (often a behaviour change specialist or clinical psychologist)
• Medical oversight from a clinician with expertise in obesity medicine
• Structured monitoring and follow-up

In practice, this means your GP cannot simply write you a Wegovy prescription on the basis of meeting the BMI criteria. You need a referral to a Tier 3 service, and that service will then initiate prescribing as part of a structured programme.

The structure is clinically appropriate. The challenge is that these services are significantly over-subscribed.

How to Get a Referral: The GP Pathway

The referral pathway looks like this in most of England:

Step 1: GP appointment. Make an appointment specifically to discuss weight management and Wegovy. Bring your weight, your BMI if you know it, and documentation of any weight-related comorbidities (medication lists, recent blood results). GPs vary widely in their knowledge of TA875. Some will refer immediately; others will be unaware or hesitant.

Step 2: GP assessment. Your GP will confirm your BMI and relevant comorbidities, check for contraindications, and complete a referral to the local Tier 3 service. If your GP is unsure or unhelpful, you can request a second opinion or ask directly to be referred for obesity assessment.

Step 3: Tier 3 assessment. The specialist service will conduct a full assessment including medical history, blood tests, dietary assessment, and psychological evaluation. This may take one appointment or several.

Step 4: Programme entry. If you meet criteria and there is capacity, you enter the weight management programme and Wegovy prescribing begins.

The realistic timeline in 2026: In most parts of England, the wait from GP referral to Tier 3 assessment is 6 to 18 months. The wait from Tier 3 assessment to starting medication is variable but can be a further 3 to 6 months in oversubscribed areas. Total time from GP referral to medication: 9 months to 2 years is not unusual.

Regional Variation: Scotland and Wales

NHS criteria and access pathways vary across the devolved nations.

Scotland: The Scottish Medicines Consortium (SMC) accepted semaglutide 2.4 mg in December 2023, with a broadly similar eligibility profile to NICE TA875. Access is through NHS specialist weight management services, with comparable waiting time challenges.

Wales: The All Wales Medicines Strategy Group (AWMSG) approved semaglutide 2.4 mg in 2024. Implementation has been slower than in England, with fewer commissioned Tier 3 services per capita. Waiting times in Wales tend to be longer.

Northern Ireland: Access follows NHS England NICE guidance for most practical purposes, with the same Tier 3 pathway structure.

Evidence Behind the Approval

The approval rests primarily on the STEP programme of trials, which established the efficacy and safety of semaglutide 2.4 mg across multiple populations.

The SELECT trial, published in 2023, added cardiovascular outcome data that strengthened the case for NHS investment:

The SELECT cardiovascular data matters for NHS access: it makes the health-economic case for Wegovy significantly stronger, as the medication is now preventing expensive cardiovascular events in a high-risk population.

While You Wait: Your Options

If you meet the NHS criteria and have been referred, getting on the waiting list is the right first step. The referral date matters; getting that clock started now means a shorter wait from today to treatment.

In the meantime, the options are:

Private treatment. Wegovy is available privately through a number of regulated UK clinics. Private prescriptions require a proper medical assessment (any reputable clinic will require this). Monthly costs range from approximately £160 to £260 depending on dose and clinic. This is not affordable for everyone, but for those who can manage it, it provides access to treatment now rather than in 18 months.

Mounjaro (tirzepatide) privately. Mounjaro typically costs £180 to £300 per month privately but produces greater average weight loss (approximately 20-22% versus 15% for semaglutide). See Mounjaro vs Wegovy for women for a comparison.

GP-led monitoring while waiting. Ask your GP to monitor your weight, blood pressure, blood glucose, and lipid profile every 3 to 6 months while you wait. This builds a documented clinical record that is useful when you reach the Tier 3 assessment.

Lifestyle support. NHS Digital Weight Management Programme is available online for people with a BMI over 30 who have type 2 diabetes, hypertension, or both. This is separate from Wegovy prescribing but provides dietitian-led support while waiting.

GP Conversations: What to Say

If your GP is unfamiliar with TA875 or resistant to referring, these are the relevant points to raise:

• NICE TA875 was published in March 2023 and recommends semaglutide 2.4 mg for adults with BMI 35+ and a comorbidity, or BMI 40+
• You are asking for a referral to the local Tier 3 specialist weight management service, not a direct GP prescription
• You understand there is a waiting list and want to join it now
• You would like your BMI and relevant comorbidities formally documented in your notes ahead of the referral

If your GP declines, you can request a second opinion. You can also contact your local Integrated Care Board (ICB) directly to ask which services are commissioned for TA875 delivery in your area.

Monitoring Before and After Starting

Baseline blood tests before starting any GLP-1 medication are valuable regardless of whether you access the medication via NHS or private route. A Tier 3 service will typically run these as part of their assessment, but having your own baseline is useful.

For a full guide to what tests to run and why, see blood tests before starting GLP-1. Women with PCOS should also review the GLP-1 and PCOS guide, as PCOS metabolic complications are a qualifying comorbidity under TA875.

For side effect preparation and what to expect in the first month, see GLP-1 side effects guide and first month on GLP-1.

The Bigger Picture

The NHS NICE approval for Wegovy is a policy achievement that reflects the strength of the evidence. The implementation gap, the distance between approved access and actual available capacity, is the immediate challenge.

The SELECT cardiovascular outcome data is likely to accelerate commissioning. Preventing heart attacks and strokes in high-risk overweight adults is economically compelling in a way that weight loss alone was not. NHS England has acknowledged the capacity challenge and committed to expanding Tier 3 services, but this takes time to build.

The realistic picture: if you meet the criteria, make the referral now. If you can access private treatment while waiting, the clinical benefits of starting sooner are real. The NHS pathway will eventually get to you. But "eventually" is a variable.